Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo

por Yang, Zhi-Ran, Chen, Zhi-Gao, Du, Xue-Mei, Li, Yan
Publicado 2020

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study

por Yang, Zhi-Ran, Su, Yan-Dong, Ma, Ru, Wu, He-Liang, Li, Yan
Publicado 2022

NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine

por Wu, He-liang, Yang, Zhi-ran, Yan, Li-jun, Su, Yan-dong, Ma, Ru, Li, Yan
Publicado 2022

Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases

por Wu, He-liang, Yang, Zhi-ran, Su, Yan-dong, Ma, Ru, Du, Xue-mei, Gao, Ying, Li, Yan
Publicado 2022

Establishment of patient‐derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal inje...

por Lin, Yu‐Lin, Zhang, Jue, Yan, Feng‐Cai, Jiang, Xi, Ma, Ru, Yang, Zhi‐Ran, Xu, Hong‐Bin, Peng, Zheng, Chen, Qian, Li, Yan
Publicado 2019

Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma

por Yang, Zhi-Ran, Chen, Zhi-Gao, Ji, Zhong-He, Lin, Yu-Lin, Zhang, Jue, Ma, Ru, Li, Zhao, Jiang, Xi, Chen, Qian, Du, Xue-Mei, Li, Yan
Publicado 2021